Silvia Novello, MD, PhD, on NSCLC: Pharmacogenomics-Driven vs Standard Adjuvant Chemotherapy

February 03, 2021 By The ASCO Post Staff
Silvia Novello, MD, PhD, of the University of Turin, discusses phase III results from the ITACA trial, which explored the notion of improving survival by customizing treatment and reducing toxicities for patients with completely resected stage II to IIIA non–small cell lung cancer (Abstract PS01.04).

Related Content